Regulatory-first CDMO · Since 2016
API and intermediates manufacturing serving 20+ countries with 8+ years of clean regulatory inspections. WHO-GMP, MHRA-aligned, cGMP throughout.
From literature review through commercial supply — one point of contact, one QA framework, one auditable chain of custody.
End-to-end contract development and manufacturing under one QA framework.
GMP-compliant multi-tonne API production with full analytical release.
Method development, ICH Q2 validation, QC, and stability under one roof.
Literature review to a validated synthesis in 8–14 weeks, cost-scored.
Lab → pilot → commercial scale-up with signed transfer protocols.
Small-molecule discovery, process R&D, and green-chemistry alternatives.
From ANVISA in Brazil to the HSA in Singapore, we prepare market-specific dossiers and stand behind our chemistry at every inspection. Explore where we ship, who we've registered with, and the local partners on the ground.
Explore global presenceSmall-molecule expertise spanning oncology to rare disease. Each area is anchored to specific route-scouting playbooks and QC libraries.
Small-molecule NCEs, kinase inhibitors, cytotoxics
ACE inhibitors, statins, anticoagulants
Antipsychotics, antidepressants, anticonvulsants
Antibacterials, antifungals, antivirals
Anti-diabetic, lipid-lowering agents
Bronchodilators, corticosteroids
Topicals, keratolytics
Orphan indications with tight process control
Featured case
A greenfield route scouting engagement for a European client's on-patent molecule. Six months from literature review to a validated three-step route that halved solvent usage and cleared regulatory review at the first attempt.
Sample partners — real names available under NDA
“Their route scouting team returned four viable options with real cost and PMI numbers, not just chemistry. That level of engineering discipline is rare in Indian CDMOs — and it's why we've stayed.”
The questions procurement and inspectors ask before signing a supply agreement.
The seven-stage workflow we use — with an anonymized case that cut PMI by 42%.
A candid look at where Indian CDMO capacity actually sits post-2025 expansions.
Every enquiry lands with a regulatory, R&D, or manufacturing SME. NDAs signed within one business day for confidential molecules.
Chat with us